Summary: A new meta-analysis of six randomized, placebo-controlled trials found that lithium supplementation, using conventional salts, does not significantly slow cognitive decline in people with mild cognitive impairment (MCI) or Alzheimer’s disease (AD). Although preclinical studies indicate lithium can protect against amyloid and tau pathology, those benefits were not observed in clinical outcomes with standard lithium formulations.
The investigators highlight pharmacological limitations—such as low brain bioavailability and amyloid binding of some lithium salts—that may blunt therapeutic effects. Future research is recommended to test alternative formulations, including lithium orotate, which may cross the blood–brain barrier more effectively and reduce systemic toxicity.
Key Facts:
- No clear clinical benefit: Across 435 participants in six randomized trials, lithium did not produce meaningful improvements in cognition or behavioral symptoms versus placebo.
- Formulation matters: Conventional lithium salts (for example, lithium carbonate and gluconate) may have limited brain penetration and higher amyloid binding, reducing effective central nervous system exposure.
- Directions for future research: Alternative formulations such as lithium orotate are proposed for targeted trials in early-stage AD or MCI because they may improve brain uptake and allow lower, safer doses.
Source: Fujita Health University
Background: Alzheimer’s disease is a progressive neurodegenerative disorder marked by worsening memory, cognition, and behavioral symptoms that significantly reduce quality of life. Despite long-standing research efforts, effective disease-modifying treatments remain limited, creating an urgent need for new neuroprotective approaches.
Lithium, long used as a mood stabilizer in bipolar disorder, has documented neuroprotective actions in laboratory studies. Mechanisms reported in preclinical work include inhibition of glycogen synthase kinase-3β (GSK3β), reduction of amyloid-β and phosphorylated tau accumulation, attenuation of neuroinflammation, and preservation of synaptic and axonal integrity. These effects have motivated clinical investigation of lithium as a potential agent to preserve cognition and slow AD progression.
Recent animal data by Aron and colleagues (2025) suggest that endogenous brain lithium supports cognitive resilience during aging. In mice, lithium depletion exacerbated hallmark AD pathologies—amyloid-β and phospho-tau buildup, neuroinflammation, and synaptic loss—and accelerated memory decline. Importantly, supplementation with lithium orotate prevented these pathological changes and preserved memory performance in those models, supporting the hypothesis that maintaining brain lithium homeostasis could be protective.
Translating such promising preclinical results to people requires rigorous clinical evaluation and attention to safety. Conventional clinical formulations, such as lithium carbonate, have dose-limiting systemic toxicity and may not reliably raise central nervous system lithium to effective concentrations.
To clarify the clinical evidence, a team led by Professor Taro Kishi at Fujita Health University, together with collaborators including Dr. Shinji Matsunaga, Dr. Youichi Saito, and Professor Nakao Iwata, performed a systematic review and meta-analysis of randomized, placebo-controlled trials testing lithium supplementation in individuals with MCI or AD.
The meta-analysis pooled data from six randomized controlled trials that enrolled a total of 435 participants, with treatment durations ranging from 10 weeks to 24 months. The included studies evaluated several lithium formulations—lithium carbonate, lithium gluconate, and lithium sulfate—reflecting formulations commonly used in clinical settings.
Primary outcomes focused on change in cognitive performance, most often assessed with the Alzheimer’s Disease Assessment Scale–Cognitive Subscale (ADAS-Cog). Secondary outcomes included behavioral and psychological symptom measures, adverse events, and rates of treatment discontinuation. The analysis used standardized mean differences and risk ratios with 95% confidence intervals and applied a random-effects model to account for variation among studies.
Overall, the pooled results showed no statistically significant cognitive benefit for lithium-treated participants compared with placebo. Secondary outcomes—behavioral symptoms, adverse events, and dropout rates—also did not differ meaningfully between lithium and placebo groups.
The investigators conducted meta-regression analyses and found no relationship between baseline cognitive status and the magnitude of lithium’s effect on cognitive change. In other words, participants’ starting cognitive scores did not explain variation in outcomes across studies.
Although the meta-analysis did not demonstrate a clinical advantage for conventional lithium salts, the authors emphasize several important implications. First, this work represents the most comprehensive synthesis to date of randomized clinical trials of lithium in MCI and AD, integrating published reports and registry-identified trials. Second, the lack of benefit in trials using conventional salts may reflect pharmacological limitations—high ionization and amyloid binding of some salts can reduce effective brain availability.
The authors recommend future well-designed, long-term clinical trials that evaluate alternative lithium formulations, notably lithium orotate, which preclinical data suggest may cross the blood–brain barrier more efficiently and avoid amyloid binding. Such formulations could permit lower systemic dosing and improved safety while achieving therapeutically relevant brain concentrations.
In conclusion, current randomized clinical trial evidence does not support the use of conventional lithium supplements to slow cognitive decline in people with MCI or AD. However, this meta-analysis provides a clear research direction: targeted clinical testing of newer lithium formulations and optimized dosing strategies is warranted to determine whether lithium’s neuroprotective properties can be harnessed safely and effectively in humans.
Funding information
This work was supported by JSPS KAKENHI Grant Number 15K19750.
Key Questions Answered:
A: Current randomized controlled trial evidence shows no significant cognitive benefit of conventional lithium salts compared with placebo.
A: Trials of conventional salts show no clear effect. Alternative formulations such as lithium orotate have promising preclinical profiles and merit clinical testing.
A: Animal research indicates lithium supports cognitive resilience and reduces AD-related pathology, motivating further investigation of optimized formulations and dosing in humans.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- The referenced journal paper was reviewed in full.
- Additional context was provided by editorial staff.
About this neuropharmacology and Alzheimer’s disease research news
Author: Hisatsugu Koshimizu
Source: Fujita Health University
Contact: Fujita Health University
Image: The image is credited to Neuroscience News
Original Research: Open access. “Lithium for Alzheimer’s disease: Insights from a meta-analysis” by Taro Kishi et al., published in Neuroscience and Behavioral Reviews.
Abstract
Lithium for Alzheimer’s disease: Insights from a meta-analysis
The authors reference Aron et al. (2025), who reported that endogenous brain lithium helps preserve cognition during aging and that lithium orotate supplementation prevented AD-like pathology and memory loss in mouse models. Prior clinical meta-analyses produced mixed findings. To resolve these inconsistencies, the current random-effects meta-analysis incorporated six randomized controlled trials of lithium supplementation in individuals with MCI and AD, aiming to detect modest but clinically meaningful effects on cognitive decline.